急性心不全(Acute Heart Failure)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Heart Failure Overview 7
Therapeutics Development 8
Pipeline Products for Acute Heart Failure – Overview 8
Pipeline Products for Acute Heart Failure – Comparative Analysis 9
Acute Heart Failure – Therapeutics under Development by Companies 10
Acute Heart Failure – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Acute Heart Failure – Products under Development by Companies 15
Acute Heart Failure – Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Anexon, Inc. 17
Angion Biomedica Corp. 18
Bayer AG 19
Lee’s Pharmaceutical Holdings Limited 20
Novartis AG 21
Nyken BV 22
Ono Pharmaceutical Co., Ltd. 23
PhaseBio Pharmaceuticals, Inc. 24
Trevena, Inc. 25
Acute Heart Failure – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ANG-4011 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ANX-042 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BR-5489 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cenderitide – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
istaroxime – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NYK-1112 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
omecamtiv mecarbil – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ONO-4232 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PB-1046 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
serelaxin – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TRV-027 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TRV-120023 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ularitide – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Acute Heart Failure – Recent Pipeline Updates 56
Acute Heart Failure – Dormant Projects 68
Acute Heart Failure – Discontinued Products 69
Acute Heart Failure – Product Development Milestones 70
Featured News & Press Releases 70
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70
Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 72
May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 73
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 74
Mar 25, 2014: FDA Staff Says Novartis’ Serelaxin Shouldn’t Be Approved 74
Jan 24, 2014: Novartis Europharm’s Reasanz Receives CHMP Negative Opinion 75
Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78